12:14 PM EDT, 10/20/2025 (MT Newswires) -- Replimune Group's ( REPL ) shares more than doubled amid heavy trading after the company said Monday that the US Food and Drug Administration accepted the resubmission of its biologics license application for RP1, in combination with nivolumab, to treat advanced melanoma.

More than 88.7 million shares traded intraday compared with a daily average of about 10 million.

Celcuity ( CELC ) said Monday it completed patient enrollment in a phase 3 trial to treat patients with breast cancer.

Shares surged 42% as intraday trading volume soared to over 4.7 million from a daily average of roughly 1.6 million.

Rapt Therapeutics ( RAPT ) and Shanghai Jeyou Pharmaceutical said Monday that their jointly developed therapy, RPT904, dosed at eight-week or 12-week intervals in a mid-stage trial was about as effective and safe as omalizumab dosed every four weeks.

Shares of Rapt Therapeutics ( RAPT ) jumped 16%, with intraday trading volume at over 2.8 million compared with a daily average of about 176,000.

Price: 10.00, Change: +5.50, Percent Change: +122.22